Publications

Biosimilars and the issue of duplicates

par Dr Paul England et Matthew Royle, Ph.D.

Intellectual Property in the Life Sciences, in review

par Dr Paul England

The UK backs the UPC and Unitary Patent

par Dr Paul England

Life Sciences Issues in Corporate Transactions - Part 1

par Colin McCall

Upgrading the single market: updating the Bolar exemption

par Dr Paul England

Upgrading the single market: a unitary SPC?

par Dr Paul England

The challenge of true IP harmonisation - Part 2

par Dr Paul England

A changing industry and changing rights

par Dr Paul England

Largest damages award on cross-undertaking upheld on appeal

par Dr Paul England

Strategic considerations - why opt-out or why not?

par Dr. Anja Lunze, LL.M.